| Style | Citing Format |
|---|---|
| MLA | Bahrami S, et al.. "Thalamic Atrophy in Active and Inactive Secondary Progressive Multiple Sclerosis Patients: A Comparative Study." Caspian Journal of Internal Medicine, vol. 17, no. 3, 2026, pp. 595-602. |
| APA | Bahrami S, Ramezani N, Panah M Y, Vaheb S, Mirmosayyeb O, Davanian F, Golparvar S, Adibi I, Shaygannejad V (2026). Thalamic Atrophy in Active and Inactive Secondary Progressive Multiple Sclerosis Patients: A Comparative Study. Caspian Journal of Internal Medicine, 17(3), 595-602. |
| Chicago | Bahrami S, Ramezani N, Panah M Y, Vaheb S, Mirmosayyeb O, Davanian F, Golparvar S, Adibi I, Shaygannejad V. "Thalamic Atrophy in Active and Inactive Secondary Progressive Multiple Sclerosis Patients: A Comparative Study." Caspian Journal of Internal Medicine 17, no. 3 (2026): 595-602. |
| Harvard | Bahrami S et al. (2026) 'Thalamic Atrophy in Active and Inactive Secondary Progressive Multiple Sclerosis Patients: A Comparative Study', Caspian Journal of Internal Medicine, 17(3), pp. 595-602. |
| Vancouver | Bahrami S, Ramezani N, Panah M Y, Vaheb S, Mirmosayyeb O, Davanian F, et al.. Thalamic Atrophy in Active and Inactive Secondary Progressive Multiple Sclerosis Patients: A Comparative Study. Caspian Journal of Internal Medicine. 2026;17(3):595-602. |
| BibTex | @article{ author = {Bahrami S and Ramezani N and Panah M Y and Vaheb S and Mirmosayyeb O and Davanian F and Golparvar S and Adibi I and Shaygannejad V}, title = {Thalamic Atrophy in Active and Inactive Secondary Progressive Multiple Sclerosis Patients: A Comparative Study}, journal = {Caspian Journal of Internal Medicine}, volume = {17}, number = {3}, pages = {595-602}, year = {2026} } |
| RIS | TY - JOUR AU - Bahrami S AU - Ramezani N AU - Panah M Y AU - Vaheb S AU - Mirmosayyeb O AU - Davanian F AU - Golparvar S AU - Adibi I AU - Shaygannejad V TI - Thalamic Atrophy in Active and Inactive Secondary Progressive Multiple Sclerosis Patients: A Comparative Study JO - Caspian Journal of Internal Medicine VL - 17 IS - 3 SP - 595 EP - 602 PY - 2026 ER - |